Major Depression
Conditions
Keywords
depression, ketamine, fMRI
Brief summary
Targeting the glutamatergic system to treat depression is a new and promising strategy based on studies at the molecular, synaptic, and neuronal level but also on results of studies conducted in animal models and first clinical studies involving depressed patients.Ketamine has been proposed as a novel approach to induce rapid antidepressant response. In this pilot project the investigators aim to introduce this novel and promising approach into clinical practice. Besides the assessment of clinical efficacy, the investigators will put a special emphasis on the assessment of ketamine-associated effects on brain function using fMRI and cognitive testing.
Interventions
DRUGKetamine
Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
Sponsors
Markus KOSEL
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Men and women aged 18 to 65 years with a diagnosis of major depressive disorder without psychotic features. * Drug-resistant depressed patients (defined as non-response to two sufficiently long (at least 6 weeks) drug trials at the maximal authorized or tolerated dose) * Score 25 or higher on the Montgomery-Asberg Depression Rating Scale * Stable psychotropic medication (antidepressants, antipsychotics, mood stabilizers) during the last 6 weeks prior to inclusion. * Legally competent subjects agreeing to comply with the requirements of the study and authorizing the transmission of relevant information to competent physicians in the case of a clinically relevant previously unknown finding during an MRI examination.
Exclusion criteria
* Subjects with co-morbid substance abuse or dependence during the 3 months prior to inclusion, except nicotine consumption. * Patients judged to be at serious suicide risk (score ≥ 4 at item 10 of the MADRS). * Patients with any other DSM-IV axis one diagnosis including bipolar disorder except for anxiety disorder which are not dominating the clinical presentation. * History of antidepressant or substance-induced hypomania or mania. * History of psychotic symptoms. * Patients with any contra-indication to the administration of ketamine, especially present diagnosis or antecedents of clinically relevant cardiovascular disorders (clinically significant or not adequately treated hypertension, present or previous diagnosis of cardiovascular disorder such as stroke or heart attack etc). * Any MRI contraindication, especially metallic implants, pacemaker, etc. * Pregnant women, breast-feeding women, women of childbearing age without effective means of contraception. * Treatment during the last 2 weeks with thyroid hormones and sympathicomimetic drug. * Present or past diagnosis of eclampsia or preeclampsia. * Untreated or insufficiently treated hyperthyroidism. * Known hypersensitivity to ketamine or to the excipient (benzethonium chloride). * Present or past diagnosis of glaucoma, intracranial hypertension.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference of the MADRS score at baseline and after ketamine injection | 40, 80, 110, 230 min, 1, 2, 3, 6, 7, 10 d after ketamine administration |
Countries
Switzerland
Outcome results
None listed